Regulatory approval

Published by the Health Service Executive. Withdrawn

The Republic of Ireland's Health Service Executive (HSE) has approved loralatinib for reimbursement as a monotherapy treatment option for adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

This is written in the approval document as:

As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously not treated with an ALK inhibitor.

Reimbursement

N/A

Citation

Lorlatinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6889/570_V3_Lorlatinib_therapy_.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2020-10-01	Health Service Executive	Indication approved for reimbursement.